

functional studies of cold stored platelets, clinical studies, and the potential role of cold stored platelets in clinical care in military and civilian patient populations. The committee will also discuss the clinical studies needed to support the indications for use of cold stored platelet products stored beyond 3 days.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's website after the meeting. Background material is available at <https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm>. Scroll down to the appropriate advisory committee meeting link. For those unable to attend in person, the meeting will also be webcast; please see the following link for webcast and other meeting information: <https://www.fda.gov/advisory-committees/blood-products-advisory-committee/2019-meeting-materials-blood-products-advisory-committee>.

Procedure: On November 22, 2019, from 8:30 a.m. to 4:45 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 13, 2019. Oral presentations from the public will be scheduled between approximately 2:35 p.m. and 3:35 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 4, 2019. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 5, 2019.

Persons attending FDA's advisory committee meetings are advised that the Agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with disabilities. If you require accommodations due to a disability, please contact Christina Vert (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our website at: <https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm> for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 26, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–21399 Filed 10–1–19; 8:45 am]
BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Charter Renewal for the Advisory Committee on Infant Mortality

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: In accordance with the Federal Advisory Committee Act, HHS is hereby giving notice that the Advisory Committee on Infant Mortality (ACIM or the Committee) has been renewed.

DATES: The effective date of the charter renewal is September 30, 2019.

FOR FURTHER INFORMATION CONTACT: David S. de la Cruz, Ph.D., MPH, Designated Federal Official (DFO), HRSA, Maternal and Child Health Bureau, 5600 Fishers Lane, 18N25, Rockville, Maryland 20857; 301–443–0543; or dcruz@hrsa.gov.

SUPPLEMENTARY INFORMATION: ACIM is authorized by section 222 of the Public Health Service Act (42 U.S.C. 217a), as amended. The Committee is governed by provisions of Public Law 92–463, as amended, (5 U.S.C. App. 2), which sets forth standards for the formation and use of Advisory Committees. ACIM advises the Secretary of HHS on department activities and programs directed at reducing infant mortality and improving the health status of pregnant women and infants. ACIM

represents a public-private partnership at the highest level to provide guidance and focus attention on the policies and resources required to address the reduction of infant mortality and the improvement of the health status of pregnant women and infants. With a focus on life course, the Committee also addresses disparities in maternal health to improve maternal health outcomes, including preventing and reducing maternal mortality and severe maternal morbidity. The Committee also provides advice on how best to coordinate the myriad of federal, state, local, and private programs and efforts that are designed to deal with the health and social problems impacting infant mortality and maternal health.

The charter renewal for ACIM was approved on September 30, 2019, which also stands as the filing date. Renewal of the ACIM charter gives authorization for the Committee to operate until September 30, 2021. A copy of the ACIM charter is available on the ACIM website at <https://www.hrsa.gov/advisory-committees/infant-mortality/index.html>. A copy of the charter also can be obtained by accessing the FACA database that is maintained by the Committee Management Secretariat under the General Services Administration. The website address for the FACA database is <http://www.facadatabase.gov/>.

Maria G. Button,
Executive Secretariat.
[FR Doc. 2019–21439 Filed 10–1–19; 8:45 am]
BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Performance Review Board Members

Title 5, U.S.C. Section 4314(c)(4) of the Civil Service Reform Act of 1978, Public Law 95–454, requires that the appointment of Performance Review Board Members be published in the **Federal Register**.

The following persons may be named to serve on the Performance Review Boards from 2019 to 2021, which oversee the evaluation of performance appraisals and compensation for Senior Executive Service, Senior Level/Senior Technical, and Title 42 executive equivalent members of the Department of Health and Human Services.

Last name	First name
AGNEW	ANN
ALEXANDER	THOMAS
ALVAREZ	JUAN CARLOS
AMES	KAREN

Last name	First name	Last name	First name
AMIN	STACY	MORSE	SARA
ANTHONY	ELISE	MOTSIOPOULOS	CHRISTOS
ARBES	SARAH	MOUGHALIAN	JENNIFER
ARMSTRONG	REBEKAH	MURPHY	PATRICK
ARNOLD	SHARON	NAIMON	DAVID
ARRIETA	JOSE	NOLAN	JANET
BARRON	PAMELA	NOONAN	TIMOTHY
BARRY	DANIEL	NOVY	STEVEN
BELL	THOMAS	OWENS	ARNE
BENOR	DAVID	PARKER	JAMES
BERGER	DANIEL	PEREZ	LUIS
BHARGAVA	DEEPAK	PERSON	LISA
BIRD	CATHERINE	PETILLO	JOHN
BLACKWELL	EDITH	PETTI	DANA
BOWMAN	MATTHEW	PHILLIPS	SALLY
BRADY	WILLIAM	PIERCE	JULIA
BRATCHER-BOW- MAN	NIKKI	POSNACK	STEVEN
BROWN	MARK	RICE	GAREY
BUREL	WILLIAM	ROBINSON	WILMA
BURNSZYNSKI	JENNIFER	ROHALL	ANNE
BUSH	LAINA	ROSKEY	COLIN
CASH	LESTER	ROWELL	SCOTT
CHAMBERS	GEORGE	ROYCE	SHANNON
CHANG	WILLIAM	RUCKER	DONALD
CLEARY	KELLY	SAMPLE	ALLEN
COCHRAN	NORRIS	SAUNDERS	MICHAEL
CONLEY	MARY	SCHUHAM	AARON
CORDOVA	JON	SEVERINO	ROGER
CORMIER	JUSTIN	SHUY	BRYAN
CRONIN	KELLY	SIGOUNAS	GEORGE
CULPEPPER	MICHAEL	SIMCOX	EDWIN
DASHER	DAVID	SIMPSON	TODD
DAVIS	MICHELLE	SKEADAS	CHRISTOS
DELEW	NANCY	STANNARD	PAULA
DESTRO	BRENDA	STEELE	DANIELLE
DORN	ALAN	STIMSON	BRIAN
DUNCAN	JAMES	TOBIAS	CONSTANCE
FINK	DOROTHY	TRUEMAN	LAURA
FISCHMANN	ELIZABETH	VALENTINE	STEVEN
FISHER	BARBARA	VITEK	TRACI
FOLEY	DEBORAH	VOGEL	JANET
FROHBOESE	ROBINSUE	WALKER	EDWIN
GABRIEL	EDWARD	WEBER	MARK
GOULDING	MICHAEL	WILLIAMS	RASHEED
GRAHAM	JOHN	WRIGHT	DONALD
GREENE	JONATHAN	WYNNE	MARGARET
GRIGSBY	GLENN		
HALL	WILLIAM		
HALL	RANDALL		
HARRISON	BRIAN		
HASELTINE	AMY		
HECHT	JONAH		
HOCKER	JULIE		
HOFFMAN	JANICE		
HOFFMAN	DARRELL		
HORN	DAVID		
JONES	CHRISTINE		
JONES	WANDA		
KAPPELER	EVELYN		
KECKLER	CHARLES		
KERR	LAWRENCE		
KOCHER	PAULA		
KRETSCHMAIER	A MICHON		
LAZARE	MARY		
LEIDER	BRENNA		
LEWIS	TERESA		
LYONS	SUSAN		
MANGO	PAUL		
MCCABE	WILLIAM		
MCDANIEL	EILEEN		
MCMILLEN	CHERYL		
MILNE	KEVIN		
MORAN	THOMAS		

Dated: September 27, 2019.

Diane C. Williamson,

Director, Executive Resources Division.

[FR Doc. 2019-21448 Filed 10-1-19; 8:45 am]

BILLING CODE 4151-17-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose

confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR-17-339: Science Education Partnership Awards (SEPA).

Date: October 28-29, 2019.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Hotel Monaco, 700 F Street NW, Washington, DC 20001.

Contact Person: Jonathan Arias, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5170, MSC 7840, Bethesda, MD 20892, (301) 435-2406, ariasj@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Cellular, Molecular and Integrative Reproduction Study Section.

Date: October 29, 2019.

Time: 1:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military Road NW, Washington, DC 20015.

Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451-6319, rojasr@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Linking Provider Recommendation to Adolescent HPV Uptake.

Date: October 29, 2019.

Time: 12:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Tasmeen Weik, DRPH, MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3141, Bethesda, MD 20892, (301) 827-6480, weikts@mail.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Prevention.

Date: October 29, 2019.

Time: 12:00 p.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: Syed M. Quadri, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6210, MSC 7804, Bethesda, MD 20892, (301) 435-1211, quadris@csr.nih.gov.